<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR32">
 <label>32.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Huizinga</surname>
    <given-names>TW</given-names>
   </name>
   <name>
    <surname>Fleischmann</surname>
    <given-names>RM</given-names>
   </name>
   <name>
    <surname>Jasson</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Radin</surname>
    <given-names>AR</given-names>
   </name>
   <name>
    <surname>van Adelsberg</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Fiore</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial</article-title>
  <source>Ann Rheum Dis</source>
  <year>2014</year>
  <volume>73</volume>
  <fpage>1626</fpage>
  <lpage>1634</lpage>
  <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204405</pub-id>
  <?supplied-pmid 24297381?>
  <pub-id pub-id-type="pmid">24297381</pub-id>
 </element-citation>
</ref>
